Abstract:Macrocyclic peptides are predominantly peptide structures bearing one or more rings and spanning multiple amino acid residues. Macrocyclization has become a common approach for improving the pharmacological properties and bioactivity of peptides. A variety of ribosomal-derived and non-ribosomal synthesized cyclization approaches have been established. The biosynthesis of backbone macrocyclic peptides using seven new emerging methodologies will be discussed with regard to the features and strengths of each platform rather than medicinal chemistry tools. The mRNA display variant, known as the random nonstandard peptide integrated discovery (RaPID) platform, utilizes flexible in vitro translation (FIT) to access macrocyclic peptides containing nonproteinogenic amino acids (NAAs). As a new discovery approach, the ribosomally synthesized and post-translationally modified peptides (RiPPs) method involves the combination of ribosomal synthesis and the phage screening platform together with macrocyclization chemistries to generate libraries of macrocyclic peptides. Meanwhile, the split-intein circular ligation of peptides and proteins (SICLOPPS) approach relies on the in vivo production of macrocyclic peptides. In vitro and in vivo peptide library screening is discussed as an advanced strategy for cyclic peptide selection. Specifically, biosynthetic bicyclic peptides are highlighted as versatile and attractive modalities. Bicyclic peptides represent another type of promising therapeutics that allow for building blocks with a heterotrimeric conjugate to address intractable challenges and enable multimer complexes via linkers. Additionally, we discuss the cell-free chemoenzymatic synthesis of macrocyclic peptides with a non-ribosomal catalase known as the non-ribosomal synthetase (NRPS) and chemo-enzymatic approach, with recombinant thioesterase (TE) domains. Novel insights into the use of peptide library tools, activity-based two-hybrid screening, structure diversification, inclusion of NAAs, combinatorial libraries, expanding the toolbox for macrocyclic peptides, bicyclic peptides, chemoenzymatic strategies, and future perspectives are presented. This review highlights the broad spectrum of strategy classes, novel platforms, structure diversity, chemical space, and functionalities of macrocyclic peptides enabled by emerging biosynthetic platforms to achieve bioactivity and for therapeutic purposes.

Frontier Between Cyclic Peptides and Macrocycles

Biosynthetic Strategies for Macrocyclic Peptides

Form and Function in Cyclic Peptide Natural Products: A Pharmacokinetic Perspective

Recent Advances in Peptide Macrocyclization Strategies.

Peptide/protein-based Macrocycles: from Biological Synthesis to Biomedical Applications

Cyclic peptide therapeutics: past, present and future

Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals

Current Synthetic Approaches to Peptide and Peptidomimetic Cyclization

Cyclic Peptides with Antifungal Properties Derived from Bacteria, Fungi, Plants, and Synthetic Sources

Cyclic peptides: a powerful instrument for advancing biomedical nanotechnologies and drug development

Biocompatible Strategies for Peptide Macrocyclisation

Cyclic Peptides in Pipeline: What Future for These Great Molecules?

Natural and Man-Made Cyclic Peptide-Based Antibiotics

Advancing multicomponent strategies to macrobicyclic peptides

Large Libraries of Structurally Diverse Macrocycles Suitable for Membrane Permeation

Recent Developments in Peptide Macrocyclization

Membrane Permeability in a Large Macrocyclic Peptide Driven by a Saddle-Shaped Conformation

Current synthetic chemistry towards cyclic antimicrobial peptides

The Missing Link(er): A Roadmap to Macrocyclization in Drug Discovery

A new class of macrocyclic peptides

Expanding the chemical space of synthetic cyclic peptides using a promiscuous macrocyclase from prenylagaramide biosynthesis